Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant

Michael Leung; Jane E. Rogers; Imad Shureiqi

doi:10.1016/j.clcc.2021.03.002

Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant

Michael Leung, Jane E. Rogers, Imad Shureiqi

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

• Delayed severe toxicities can occur after fluoropyrimidine exposure in patients with heterozygous DPYD mutation genotypes, especially with DPD c.557A>G (p.Y186C) variant in patients of African descent and female sex. • Uridine triacetate treatment should not be limited to patients with early-onset fluoropyrimidine toxicities or homozygous DPYD mutations.

Original language	English (US)
Pages (from-to)	273-278
Number of pages	6
Journal	Clinical colorectal cancer
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.clcc.2021.03.002
State	Published - Sep 2021

Keywords

African American
Fluoropyrimidine
Fluoropyrimidine chemotherapy toxicity
Pharmacogenomic
p.Y186C

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1016/j.clcc.2021.03.002

Cite this

@article{dbebdb5ecf6f428ba6bcf54f3f93f0a8,

title = "Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant",

abstract = "• Delayed severe toxicities can occur after fluoropyrimidine exposure in patients with heterozygous DPYD mutation genotypes, especially with DPD c.557A>G (p.Y186C) variant in patients of African descent and female sex. • Uridine triacetate treatment should not be limited to patients with early-onset fluoropyrimidine toxicities or homozygous DPYD mutations.",

keywords = "African American, Fluoropyrimidine, Fluoropyrimidine chemotherapy toxicity, Pharmacogenomic, p.Y186C",

author = "Michael Leung and Rogers, {Jane E.} and Imad Shureiqi",

note = "Funding Information: The authors declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = sep,

doi = "10.1016/j.clcc.2021.03.002",

language = "English (US)",

volume = "20",

pages = "273--278",

journal = "Clinical colorectal cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant

AU - Leung, Michael

AU - Rogers, Jane E.

AU - Shureiqi, Imad

PY - 2021/9

Y1 - 2021/9

N2 - • Delayed severe toxicities can occur after fluoropyrimidine exposure in patients with heterozygous DPYD mutation genotypes, especially with DPD c.557A>G (p.Y186C) variant in patients of African descent and female sex. • Uridine triacetate treatment should not be limited to patients with early-onset fluoropyrimidine toxicities or homozygous DPYD mutations.

AB - • Delayed severe toxicities can occur after fluoropyrimidine exposure in patients with heterozygous DPYD mutation genotypes, especially with DPD c.557A>G (p.Y186C) variant in patients of African descent and female sex. • Uridine triacetate treatment should not be limited to patients with early-onset fluoropyrimidine toxicities or homozygous DPYD mutations.

KW - African American

KW - Fluoropyrimidine

KW - Fluoropyrimidine chemotherapy toxicity

KW - Pharmacogenomic

KW - p.Y186C

UR - http://www.scopus.com/inward/record.url?scp=85105328945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105328945&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2021.03.002

DO - 10.1016/j.clcc.2021.03.002

M3 - Article

C2 - 33965356

AN - SCOPUS:85105328945

SN - 1533-0028

VL - 20

SP - 273

EP - 278

JO - Clinical colorectal cancer

JF - Clinical colorectal cancer

IS - 3

ER -

Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this